Opto Circuits gets DCGI nod for heart device

Medical equipment maker Opto Circuits today said it has received approval from India's health regulator for a medical device for heart patients, following which it has launched the product in the market.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead GrowMyMoney IThe Winning Leap SME Special
Moneycontrol

Home » News » Business

Sep 11, 2012, 08.20 AM | Source: PTI

Opto Circuits gets DCGI nod for heart device

Medical equipment maker Opto Circuits today said it has received approval from India's health regulator for a medical device for heart patients, following which it has launched the product in the market.

Like this story, share it with millions of investors on M3

Opto Circuits gets DCGI nod for heart device

Medical equipment maker Opto Circuits today said it has received approval from India's health regulator for a medical device for heart patients, following which it has launched the product in the market.

Post Your Comments

Share Cancel

Medical equipment maker Opto Circuits today said it has received approval from India's health regulator for a medical device for heart patients, following which it has launched the product in the market.

Opto Eurocor Healthcare, a subsidiary of Opto Circuits (India), launched Sirolimus Drug Eluting Stent (DES), E-Magic Plus on receipt of Drug Controller General of India (DCGI) licence to sell and market the product in India, Opto Circuits said in a statement.

A stent is a wire metal mesh tube that is used to open a blocked artery during an angioplasty.

"E-Magic Plus has been developed indigenously in India and with the DCGI mark we can market and sell in India. The DCGI approval will also enable E-Magic Plus to be marketed in parts of Far East and parts of Middle East," Opto Circuits (India) Ltd Chairman & Managing Director Vinod Ramnani said.

Sirolimus DES market is estimated to be worth Rs 800 crore in India, he added.

The DES market has two major drug categories: Sirolimus and Paclitaxel. In India, Sirolimus-based angioplasty devices have a more than 90% market share, the company said. "Opto Eurocor Healthcare Ltd will launch E-Magic Plus in the European and Latin-American market after receiving the
necessary approvals," it added.

Shares of Opto Circuits today closed at Rs 129.60 on the BSE, down 0.96% from previous closing.

Buy, Hold, Sell ? Hear it first on M3
Opto Circuits gets DCGI nod for heart device

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login